RNA, U6 small nuclear 1157, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-1157P profile across patient tissues and cancer cell-line models. RNU6-1157P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNU6-1157P is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RNU6-1157P RNA expression shows 16,765 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where RNU6-1157P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-1157P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-1157P survival associations across molecular data types. RNU6-1157P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-1157P RNA expression–survival associations across cancer types. High RNU6-1157P expression shows unfavorable associations in UVM, LIHC and PRAD, but favorable associations in HNSC, BLCA and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for RNU6-1157P RNA expression.
This table summarizes RNU6-1157P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-1157P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-1157P shows higher tumor expression in KIRC, BLCA, STAD, LUAD, BRCA and CHOL. The KIRC box plot shows higher RNU6-1157P RNA expression in tumor versus normal tissue (log2 FC = +0.380, t-test p < 0.001).
This table shows molecular features associated with RNU6-1157P in patient tissues and cancer cell lines. In patient samples, RNU6-1157P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
